
- /
- Supported exchanges
- / US
- / FENC.NASDAQ
Fennec Pharmaceuticals Inc (FENC NASDAQ) stock market data APIs
Fennec Pharmaceuticals Inc Financial Data Overview
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Fennec Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Fennec Pharmaceuticals Inc data using free add-ons & libraries
Get Fennec Pharmaceuticals Inc Fundamental Data
Fennec Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 33 302 K
- EBITDA: -9 342 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fennec Pharmaceuticals Inc News

Fennec Q2 Sales Jump 33 Percent
Fennec Pharmaceuticals (NASDAQ:FENC) reported second quarter 2025 earnings on August 14, 2025, GAAP net product sales of $9.7 million, up 33% year over year compared to the same period last year and 1...


Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss
Fennec Pharmaceuticals Inc (NASDAQ:FENC [https://www.chartmill.com/stock/quote/FENC/profile]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expect...

Fennec Pharmaceuticals GAAP EPS of -$0.11 misses by $0.08, revenue of $9.65M beats by $0.09M
* Fennec Pharmaceuticals press release [https://seekingalpha.com/pr/20200624-fennec-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:FENC [https://seeking...

Stocks Muted Before the Open With Key U.S. PPI Data in Focus
September S&P 500 E-Mini futures (ESU25) are down -0.02%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are down -0.08% this morning, taking a breather after recent gains, while investors look ahead ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.